8-K: Ocean Biomedical Lowers Conversion Price on Promissory Note

Ocean Biomedical has irrevocably lowered the conversion price of a promissory note from $1.50 to $0.01 per share for a $400,000 conversion amount.

Summary

• On March 26, 2025, Ocean Biomedical, Inc. filed a Form 8-K report.
• The report details an adjustment to a promissory note issued to an institutional investor on May 15, 2023.
• The company has irrevocably lowered the conversion price from $1.50 to $0.01 per share.
• This change applies to a $400,000 conversion amount, referred to as the Reduced Conversion Amount.
• The company is prohibited from redeeming or prepaying this Reduced Conversion Amount.

Sentiment

Score: 5

Explanation: The announcement itself is neutral, detailing a contractual adjustment. The impact on the company's financials and stock price is uncertain without further context.

Future Outlook

The document does not contain specific forward-looking statements beyond the details of the conversion price adjustment.

Industry Context

This announcement reflects a specific financial maneuver by Ocean Biomedical, potentially to manage its debt obligations or incentivize conversion of debt to equity. The impact on the company's capital structure and shareholder equity will depend on the investor's decision to convert the note at the new price.

Key Dates

Keywords

promissory note, conversion price, Ocean Biomedical, financing, conversion